Medical Policy Updates

Table Of Contents

Notification of Policy Revisions Effective January 1, 2014 (Posted October 1, 2013)

Medical Policy Revision
Golimumab (Simponi) "Notification" New medical policy issued. Golimumab (Simponi) may be medically necessary for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and moderate to severe ulcerative colitis. Notification given 10/1/13 for effective date 1/1/14.